APO-RIVASTIGMINE PATCH 10 rivastigmine 9.5 mg/24 hours transdermal drug delivery system sachet

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

rivastigmine, Quantity: 18 mg

Available from:

Arrotex Pharmaceuticals Pty Ltd

INN (International Name):

Rivastigmine

Pharmaceutical form:

Drug delivery system, transdermal

Composition:

Excipient Ingredients: acrylates copolymer; ethyl acetate; methylated trimethylated silica; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer

Administration route:

Transdermal

Units in package:

7 transdermal drug delivery systems, 30 transdermal drug delivery systems

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

APO-RIVASTIGMINE is indicated for the treatment of patients with mild to moderate dementia of the Alzheimer's type.

Product summary:

Visual Identification: Circular 10cm2 transdermal patch, tri-layer adhesive matrix, translucent white backing film labelled with "Rivastigmine 9.5 mg/24 h"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2016-01-12